Solving Riddles Through Sequencing
Recruiting
Observational Study
Leukemia
Hematologic Malignancy
Rare Diseases
Refractory Leukemia
Refractory Lymphoma
Unknown Primary Tumors
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- Munich Leukemia Laboratory · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients. This continuous evolution proceeded in parallel to seminal discoveries in basic science such as FISH, PCR and NGS. So far, the current WHO classification serves as reference to diagnostic decision making and is …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients having been investigated with a suspected hematological disorder and:
* Having unclear diagnosis after internal routine diagnosis
* Unusual clinical course
* Unusual r/r status or non-responder
* Multiple parallel hematological conditions
* Difficult/rare therapy asso…
Contacts